Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records

Current Medical Research and Opinion

Volumn 28, Issue 9, 2012, Pages 1407-1414

  Rosenman, Marc B ^a,b   Baker, Layla ^b   Jing, Yonghua ^c   Makenbaeva, Dinara ^c   Meissner, Brian ^c   Simon, Teresa A ^c   Wiederkehr, Daniel ^d   Deitelzweig, Steve ^e  

^a INDIANA UNIVERSITY   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke prevention; Warfarin

Indexed keywords

WARFARIN;

AGED; AUTOMATION; BLEEDING; CLINICAL DECISION MAKING; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG USE; ELECTRONIC MEDICAL RECORD; FALL RISK; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; SINUS RHYTHM; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; STROKE; WARFARIN;

EID: 84866714172     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.708653     Document Type: Review

References (36)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics\2011 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2011; 123:e18-209
3. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003;290:1049-56
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11
5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
7. Fuster V, Rydén LE, Asinger RW, et al. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66
8. Guyatt GH, Akl EA, Crowther, M, et al. Antithrombotic therapy and the prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th edition). Chest 2012;141(Suppl):7-47S
9. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
10. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS Focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:1144-50
11. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902
12. Gattellari M, Worthington JM, Zwar NA, et al. The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: Bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract 2008;9:62
13. Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: Matched pair analysis. BMJ 2006;332:141-5
14. Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract 2004;21:290-8
15. Man-Son-Hing M, Gage BF, Montgomery AA, et al. Preference-based antith-rombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making 2005;25:548-59
16. McAlister FA, Man-Son-Hing M, Straus SE, et al. Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomised trial. CMAJ 2005;173:496-501
17. Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55-60
18. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006; 37:1070-4
19. Barnes GD, Chae S, Froehlich JB. National adherence to guidelines for stroke prevention in atrial fibrillation. Circulation 2010;122:A19549
20. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000;31:822-7
21. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-34
22. Friberg L, Hammar N, Ringh M, et al. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAFstudy). Eur Heart J 2006;27:1954-64
23. Boulanger L, Kim J, Friedman M, et al. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract 2006;60:258-64
24. Lip GY, Zarifis J, Watson RD, et al. Physician variation in the management of patients with atrial fibrillation. Heart 1996;75:200-5
25. Hylek EM, D'Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37:1075-80
26. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004;164:2044-50
27. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675-83
28. Rosenman M, Simon TA, Teal E, et al. A study of perceived or actual barriers to warfarin (VKA) in NVAF. Podium presentation at the Annual Scientific Conference of the European Society of Cardiology 2009; Barcelona, Spain
29. McDonald CJ, Overhage JM, Tierney WM, et al. The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform 1999; 54:225-53
30. McDonald CJ, Tierney WM. The Medical Gopher\A microcomputer system to help find, organize and decide about patient data. West J Med 1986; 145:823-9
31. Aalsma MC, Wiehe SE, Blythe MJ, et al. Mental health screening and STI among detained youth. J Community Health 2011;36:300-6
32. Callahan CM, Arling G, Tu W, et al. Transitions in care among older adults with and without dementia. J Am Geriatr Soc 2012;60:813-20
33. Mega J. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011;365:1052-4
34. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med 2011;365:981-92
35. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Eng J Med 2011;364:806-17
36. Lip GY. Implications of the CHA2DS2-VASc and HAS-BLED scores for throm-boprophylaxis in atrial fibrillation. Am J Med 2011;124:111-14